Therapy response correlates with ALDH activity in ALDH low-positive childhood acute lymphoblastic leukemias

Pediatric Hematology and Oncology

Volumn 31, Issue 4, 2014, Pages 303-310

  Ahlers, Jörg ^a   Witte, Kai Erik ^b   Schwarze, C Philipp ^b   Lang, Peter ^b   Handgretinger, Rupert ^b   Ebinger, Martin ^b  

^a KLINIKUM CHEMNITZ   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Acute lymphoblastic leukemia; Aldehyde dehydrogenase activity; Immature leukemic cell fraction; Minimal residual disease; Prognostic factor

Indexed keywords

ALDEHYDE DEHYDROGENASE; CD34 ANTIGEN; CD38 ANTIGEN; CD45 ANTIGEN; ANTINEOPLASTIC AGENT; LEUKOCYTE ANTIGEN; TUMOR PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ANTIGEN EXPRESSION; ARTICLE; CELL MATURATION; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; INDUCTION CHEMOTHERAPY; INFANT; LEUKEMIA CELL; MALE; MINIMAL RESIDUAL DISEASE; PHENOTYPE; TREATMENT RESPONSE; BIOSYNTHESIS; CLINICAL TRIAL; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; GENE EXPRESSION REGULATION; METABOLISM; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; TIME;

ADOLESCENT; ALDEHYDE DEHYDROGENASE; ANTIGENS, CD; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INFANT; MALE; NEOPLASM PROTEINS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TIME FACTORS;

EID: 84899070762     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880018.2013.859189     Document Type: Article

References (23)

1. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371:1030-1043.
2. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645-648.
3. Wang JC, Lapidot T, Cashman JD, et al. High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood. 1998;91:2406-2414.
4. Dick JE. Stem cell concepts renew cancer research. Blood. 2008;112:4793-4807.
5. Castor A,Nilsson L, strand-GrundstromI, et al. Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. NatMed. 2005;11:630-637.
6. Hong D, Gupta R, Ancliff P, et al. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science. 2008;319:336-339.
7. le VC, Hotfilder M, Bomken S, et al. In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell 2008;14: 47-58.
8. Kong Y, Yoshida S, Saito Y, et al. CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Leukemia. 2008;22: 1207-1213.
9. Storms RW, Trujillo AP, Springer JB, et al. Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. Proc Natl Acad Sci USA. 1999;96:9118-9123.
10. Pearce DJ, TaussigD, Simpson C, et al. Characterization of cellswith a high aldehyde dehydrogenase activity from cord blood and acutemyeloid leukemia samples. Stem Cells. 2005;23:752-760.
11. Cheung AM, Wan TS, Leung JC, et al. Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. Leukemia. 2007;21:1423-1430.
12. Ran D, Schubert M, Taubert I, et al. Heterogeneity of leukemia stem cell candidates at diagnosis of acutemyeloid leukemia and their clinical significance. Exp Hematol. 2012;40:155-165.
13. Gerber JM, Smith BD,Ngwang B, et al. A clinically relevant population of leukemic CD34(+)CD38(-) cells in acutemyeloid leukemia. Blood 2012;119:3571-3577.
14. Lin TL, Wang QH, Brown P, et al. Self-renewal of acute lymphocytic leukemia cells is limited by the Hedgehog pathway inhibitors cyclopamine and IPI-926. PLoS One. 2010;5:e15262.
15. de Figueiredo-Pontes LL, Pintao MC, Oliveira LC, et al. Determination of P-glycoprotein, MDRrelated protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acutemyeloid leukemia. Cytometry B Clin Cytom. 2008;74:163-168.
16. Misaghian N, Ligresti G, Steelman LS, et al. Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia. 2009;23:25-42.
17. Ebinger M, Witte KE, Ahlers J, et al. High frequency of immature cells at diagnosis predicts high minimal residual disease level in childhood acute lymphoblastic leukemia. Leuk Res. 2010;34: 1139-1142.
18. ChungNG, Buxhofer-Ausch V, Radich JP.The detection and significance of minimal residual disease in acute and chronic leukemia. Tissue Antigens. 2006;68:371-385.
19. Flohr T, Schrauder A, Cazzaniga G, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the internationalmulticenter trial AIEOP-BFMALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008;22:771-782.
20. van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998;352:1731-1738.
21. Campana D. Status of minimal residual disease testing in childhood haematological malignancies. Br J Haematol. 2008;143:481-489.
22. Ran D, SchubertM, Pietsch L, et al. Aldehyde dehydrogenase activity among primary leukemia cells is associated with stem cell features and correlates with adverse clinical outcomes. Exp Hematol. 2009;37:1423-1434.
23. Pei S, Jordan CT.How close are we to targeting the leukemia stem cell? Best Pract Res Clin Haematol. 2012;25:415-418.